Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - The impact of tumour rupture on patient outcomes

European Journal of Surgical Oncology

Volumn 37, Issue 10, 2011, Pages 890-896

  Rutkowski, P ^a   Bylina, E ^a   Wozniak, A ^b   Nowecki, Z I ^a   Osuch, C ^c   Matlok, M ^c   Switaj T ^a   Michej, W ^a   Wronski M ^d   Gluszek S ^e   Kroc, J ^f   Nasierowska Guttmejer, A ^g   Joensuu, H ^h  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c JAGIELLONIAN UNIVERSITY   (Poland)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

^e JAN KOCHANOWSKI UNIVERSITY   (Poland)

^f Pfizer Poland   (Poland)

^g Central Hospital   (Poland)

^h UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Gastrointestinal stromal tumour; GIST; Prognosis; Risk criteria; Surgery; Tumour rupture

Indexed keywords

STEM CELL FACTOR RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURGERY; CHILD; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; JOENSUU RISK CRITERIA; MAJOR CLINICAL STUDY; MALE; MITOSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RELAPSE FREE SURVIVAL; RISK ASSESSMENT; RUPTURE; SCHOOL CHILD; SURVIVAL; TUMOR RUPTURE; TUMOR VOLUME; VALIDATION STUDY;

ADOLESCENT; ADULT; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; CHILD; DISEASE-FREE SURVIVAL; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PIPERAZINES; PRACTICE GUIDELINES AS TOPIC; PROPORTIONAL HAZARDS MODELS; PYRIMIDINES; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RUPTURE, SPONTANEOUS; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR BURDEN; YOUNG ADULT;

EID: 80052963619     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2011.06.005     Document Type: Article

References (25)

1. S. Hirota, K. Isozaki, and Y. Moriyama Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 1998 577 580 (Pubitemid 28067289)
2. M.C. Heinrich, C.L. Corless, and A. Duensing PDGFRA activating mutations in gastrointestinal stromal tumors Science 299 2003 708 710 (Pubitemid 36159485)
3. R.P. Dematteo, K.V. Ballman, and C.R. Antonescu Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial Lancet 373 2009 1097 1104
4. C.D. Fletcher, J.J. Berman, and C. Corless Diagnosis of gastrointestinal stromal tumors: a consensus approach Hum Pathol 33 2002 459 465 (Pubitemid 34747864)
5. P. Rutkowski, Z.I. Nowecki, and W. Michej Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor Ann Surg Oncol 4 2007 2018 2027 (Pubitemid 46988258)
6. M. Miettinen, and J. Lasota Gastrointestinal stromal tumors: pathology and prognosis at different sites Semin Diagn Pathol 23 2006 70 83 (Pubitemid 44692418)
7. M. Miettinen, L.H. Sobin, and J. Lasota Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up Am J Surg Pathol 29 2005 52 68 (Pubitemid 40023952)
8. M. Miettinen, H. Makhlouf, L.H. Sobin, and J. Lasota Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up Am J Surg Pathol 30 2006 477 489 (Pubitemid 43740149)
9. G.D. Demetri, R.S. Benjamin, and C.D. Blanke NCCN Task force report: management of patients with gastrointestinal stromal tumor (GIST) - update of the NCCN clinical practice guidelines J Natl Compr Canc Netw 5 Suppl 2 2007 S1 S29
10. J.S. Gold, M. Gonen, and A. Gutierrez Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis Lancet Oncol 10 2009 1045 1052
11. H. Joensuu Risk stratification of patients diagnosed with gastrointestinal stromal tumor Hum Pathol 39 2008 1411 1419
12. T. Takahashi, K. Nakajima, and A. Nishitani An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors Int J Clin Oncol 12 2007 369 374 (Pubitemid 47573418)
13. P. Hohenberger, U. Ronellenfitsch, and O. Oladeji Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour Br J Surg 97 2010 1854 1859
14. W. Ruka, P. Rutkowski, and J. Kulig Recommendations for diagnostics and therapy of gastrointestinal stromal tumors (GIST) in 2008 Nowotwory - J Oncol 58 2008 537 549
15. M. Debiec-Rychter, H. Dumez, and I. Judson Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group Eur J Cancer 40 2004 689 695 (Pubitemid 38326618)
16. B.K. Goh, P.K. Chow, and W.M. Yap Which is the optimal risk stratification system for surgically treated localized primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal for a modified Armed Forces Institute of Pathology risk criteria Ann Surg Oncol 15 2008 2153 2163
17. NCCN The NCCN soft tissue sarcoma clinical practice guidelines in oncology (version 1, 2010). (c) 2010 National Comprehensive Cancer Network, Inc [accessed 01.07.10]. To view the most recent and complete version of the guideline, go online to www.nccn.org 2010 http://www.nccn.org
18. C.E. Woodall 3rd, G.N. Brock, and J. Fan An evaluation of 2,537 gastrointestinal stromal tumors for a proposed clinical staging system Arch Surg 144 2009 670 678
19. R.P. Dematteo, J.S. Gold, and L. Saran Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST) Cancer 112 2008 608 615 (Pubitemid 351186201)
20. E.H. Ng, R.E. Pollock, M.F. Munsell, E.N. Atkinson, and M.M. Romsdahl Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. implications for surgical management and staging Ann Surg 215 1992 68 77
21. J. Martin, A. Poveda, and A. Llombart-Bosch Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS) J Clin Oncol 23 2005 6190 6198
22. J. Lasota, and M. Miettinen Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours Histopathology 53 2008 245 266
23. E. Wardelmann, I. Losen, and V. Hans Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors Int J Cancer 106 2003 887 895 (Pubitemid 37071667)
24. J. Lasota, A. Dansonka-Mieszkowska, L.H. Sobin, and M. Miettinen A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential Lab Invest 84 2004 874 883 (Pubitemid 38833247)
25. C.L. Corless, and M.C. Heinrich Molecular pathobiology of gastrointestinal stromal sarcomas Annu Rev Pathol 3 2008 557 586 (Pubitemid 351488293)